149 related articles for article (PubMed ID: 27197055)
21. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
22. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
Kawamura M; Eguchi K; Izumi Y; Yamato Y; Koike T; Sakaguchi H; Hada E; Kobayashi K
Cancer Chemother Pharmacol; 2007 Sep; 60(4):495-501. PubMed ID: 17143600
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
Pink D; Richter S; Gerdes S; Andreou D; Tunn PU; Busemann C; Ehninger G; Reichardt P; Schuler MK
Oncology; 2014; 87(2):95-103. PubMed ID: 25011671
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Bozionelou V; Kalbakis K; Vamvakas L; Agelaki S; Androulakis N; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2009 Sep; 64(4):785-91. PubMed ID: 19159931
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.
Kuo C; Kent PM; Logan AD; Tamulonis KB; Dalton KL; Batus M; Fernandez K; Mcfall RE
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221727
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
De Castro J; Lorenzo A; Morales S; Belón J; Dorta J; Lizón J; Madroñal C; Gallurt PM; Casado E; Feliu J; Barón MG;
Cancer Chemother Pharmacol; 2005 Feb; 55(2):197-202. PubMed ID: 15322824
[TBL] [Abstract][Full Text] [Related]
31. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Leu KM; Ostruszka LJ; Shewach D; Zalupski M; Sondak V; Biermann JS; Lee JS; Couwlier C; Palazzolo K; Baker LH
J Clin Oncol; 2004 May; 22(9):1706-12. PubMed ID: 15117993
[TBL] [Abstract][Full Text] [Related]
32. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
Albertsson M; Johansson B; Friesland S; Kadar L; Letocha H; Frykholm G; Wagenius G
Med Oncol; 2007; 24(4):407-12. PubMed ID: 17917090
[TBL] [Abstract][Full Text] [Related]
33. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K
Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y
Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.
Sun L; Zhou DS; Zhang P; Li QH; Liu P
Int J Pharm; 2015 Jan; 478(1):308-317. PubMed ID: 25433201
[TBL] [Abstract][Full Text] [Related]
37. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Garcia JA; Hutson TE; Shepard D; Elson P; Dreicer R
Cancer; 2011 Feb; 117(4):752-7. PubMed ID: 20922803
[TBL] [Abstract][Full Text] [Related]
40. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
